Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Cannabidiol:

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Devinsky O et al. Epilepsia. (2014)

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Burstein S et al. Bioorg Med Chem. (2015)

Cannabidiol as a Potential Treatment for Anxiety Disorders. Blessing EM et al. Neurotherapeutics. (2015)

Search results

Items: 1 to 20 of 2077

1.

Cannabinoid signalling in the immature brain: encephalopathies and neurodevelopmental disorders.

Sagredo O, Palazuelos J, Gutierrez-Rodriguez A, Satta V, Galve-Roperh I, Martínez-Orgado J.

Biochem Pharmacol. 2018 Aug 14. pii: S0006-2952(18)30334-4. doi: 10.1016/j.bcp.2018.08.014. [Epub ahead of print] Review.

PMID:
30118663
2.

Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.

Schonhofen P, Bristot IJ, Crippa JA, Hallak JEC, Zuardi AW, Parsons RB, Klamt F.

CNS Drugs. 2018 Aug 14. doi: 10.1007/s40263-018-0550-4. [Epub ahead of print]

PMID:
30109642
3.

Pharmacological Comparisons Between Cannabidiol and KLS-13019.

Brenneman DE, Petkanas D, Kinney WA.

J Mol Neurosci. 2018 Aug 14. doi: 10.1007/s12031-018-1154-7. [Epub ahead of print]

PMID:
30109468
4.

Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.

Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program.

Epilepsy Behav. 2018 Aug 9. pii: S1525-5050(18)30473-6. doi: 10.1016/j.yebeh.2018.07.020. [Epub ahead of print]

5.

Treatment of Periodontal Ligament Stem Cells with MOR and CBD Promotes Cell Survival and Neuronal Differentiation via the PI3K/Akt/mTOR Pathway.

Lanza Cariccio V, Scionti D, Raffa A, Iori R, Pollastro F, Diomede F, Bramanti P, Trubiani O, Mazzon E.

Int J Mol Sci. 2018 Aug 9;19(8). pii: E2341. doi: 10.3390/ijms19082341.

6.

The Role of Cannabis within an Emerging Perspective on Schizophrenia.

Diviant JP, Vigil JM, Stith SS.

Medicines (Basel). 2018 Aug 8;5(3). pii: E86. doi: 10.3390/medicines5030086.

7.

Neuronal preservation and reactive gliosis attenuation following neonatal sciatic nerve axotomy by a fluorinated cannabidiol derivative.

Perez M, Cartarozzi LP, Chiarotto GB, Oliveira SA, Guimarães FS, Oliveira ALR.

Neuropharmacology. 2018 Aug 7;140:201-208. doi: 10.1016/j.neuropharm.2018.08.009. [Epub ahead of print]

PMID:
30096328
8.

Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience.

Chen KA, Farrar M, Cardamone M, Gill D, Smith R, Cowell CT, Truong L, Lawson JA.

Med J Aust. 2018 Aug 13. [Epub ahead of print]

PMID:
30092753
9.

Safety of cannabidiol prescribed for children with refractory epilepsy.

Freeman JL.

Med J Aust. 2018 Aug 13. [Epub ahead of print] No abstract available.

PMID:
30092751
10.

Effects of cannabidiol, a Cannabis sativa constituent, on oral wound healing process in rats: Clinical and histological evaluation.

Klein M, de Quadros De Bortolli J, Guimarães FS, Salum FG, Cherubini K, de Figueiredo MAZ.

Phytother Res. 2018 Aug 8. doi: 10.1002/ptr.6165. [Epub ahead of print]

PMID:
30088305
11.

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials.

Bitencourt RM, Takahashi RN.

Front Neurosci. 2018 Jul 24;12:502. doi: 10.3389/fnins.2018.00502. eCollection 2018. Review.

12.

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.

Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, Brown H, Berthelsen ES, Wakshlag JJ.

Front Vet Sci. 2018 Jul 23;5:165. doi: 10.3389/fvets.2018.00165. eCollection 2018.

13.

Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant.

Ravula A, Chandasana H, Setlow B, Febo M, Bruijnzeel AW, Derendorf H.

J Pharm Biomed Anal. 2018 Jul 19;160:119-125. doi: 10.1016/j.jpba.2018.07.004. [Epub ahead of print]

PMID:
30077950
14.

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis.

García-Martín A, Garrido-Rodríguez M, Navarrete C, Del Río C, Bellido ML, Appendino G, Calzado MA, Muñoz E.

Biochem Pharmacol. 2018 Aug 2. pii: S0006-2952(18)30317-4. doi: 10.1016/j.bcp.2018.07.047. [Epub ahead of print]

PMID:
30076848
15.

Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.

Iannotti FA, Pagano E, Moriello AS, Alvino FG, Sorrentino NC, D'Orsi L, Gazzerro E, Capasso R, De Leonibus E, De Petrocellis L, Di Marzo V.

Br J Pharmacol. 2018 Aug 3. doi: 10.1111/bph.14460. [Epub ahead of print]

PMID:
30074247
16.

Nausea-Induced 5-HT Release in the Interoceptive Insular Cortex and Regulation by Monoacylglycerol Lipase (MAGL) Inhibition and Cannabidiol.

Limebeer CL, Rock EM, Sharkey KA, Parker LA.

eNeuro. 2018 Jul 31;5(4). pii: ENEURO.0256-18.2018. doi: 10.1523/ENEURO.0256-18.2018. eCollection 2018 Jul-Aug.

17.

Molecular Genetics and New Medication Strategies for Opioid Addiction.

Hurd YL, O'Brien CP.

Am J Psychiatry. 2018 Aug 2:appiajp201818030352. doi: 10.1176/appi.ajp.2018.18030352. [Epub ahead of print]

PMID:
30068261
18.

Cannabidiol effects on behaviour and immune gene expression in zebrafish (Danio rerio).

Jensen HM, Korbut R, Kania PW, Buchmann K.

PLoS One. 2018 Jul 31;13(7):e0200016. doi: 10.1371/journal.pone.0200016. eCollection 2018.

19.

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G, Sacchetto L, Chiorino G, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M.

Oncogene. 2018 Jul 30. doi: 10.1038/s41388-018-0390-1. [Epub ahead of print]

PMID:
30061636
20.

Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.

Pichler EM, Kawohl W, Seifritz E, Roser P.

Int J Psychiatry Med. 2018 Jul 30:91217418791455. doi: 10.1177/0091217418791455. [Epub ahead of print]

PMID:
30058466

Supplemental Content

Loading ...
Support Center